Yang said the company is following the same three-phase testing protocol used in western countries and reports that so far they have tested 144 volunteers in phase I and 600 in phase II. Phase I is a small study in healthy adults to test for safety, whereas phase II is a slightly larger study testing for safety and effectiveness. Phase III is a study conducted on an even larger test group.

“The vaccine shows a good safety profile,” Yang told ABC News regarding their human trials. “We haven’t seen any severe adverse reaction after using our vaccines.”

Yang said the vaccine could finish phase III of testing by the fall — the final phase needed for the vaccine’s approval in China. Although, Yang cautioned, this timeline is dependent on the vaccine’s continued alleged success in human trials.